Search Results

The new site strengthens the company’s production capacity, sustainable industrial footprint, and support for global bioprocessing customers. • New 4,200 m² headquarters and manufacturing facility located within the Biopôle Clermont-Limagne life sciences technology park • Designed to increase manufacturing capacity by 150% for the company’s downstream purification technologies • Selected as part of the France 2030 “Industrialization and Health Capacities 2030” program • Sustainable features include photovoltaic panels, green roofing, rainwater recovery and reuse, and electric vehicle charging stations

Successful completion of GLP toxicology analysis for the intravenous administration of Rutherrin(R) lays the groundwork for regulatory submissions supporting first-in-human clinical development for multiple life-threatening cancers

Single-dose VINIA Daily Chews broaden demographics and usage occasions while demonstrating the commercial versatility of Botanical Synthesis Format expansion shows how BioHarvest can help CDMO partners move from plant-cell compositions to differentiated consumer products

Proprietary TeloView® blood-based TELO-MRD assay detected residual myeloma cells in a higher proportion of matched samples than bone-marrow next-generation flow cytometry in a University of Athens comparison.

The FDA aims to leverage the expertise of qualified research institutions paired with drug sponsors to lessen the risk of clinical holds during the investigational new drug review process and expedite the path to first-in-human development in the U.S. The initial application period will close on Oct. 30.